All In Biotech

Investigational drug · Phase 3

Exendin-4 Fc fusion protein

Also called: JY09

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type2 Diabetes Mellitus, Type 2 Diabetes Mellitus.

Phase 3

Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

3

Any phase or sponsor naming "Exendin-4 Fc fusion protein"

First trial start

2024

Jul 10, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Exendin-4 Fc fusion protein", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Type2 Diabetes Mellitus
  • Type 2 Diabetes Mellitus

Approved drugs for the same conditions: Type 2 diabetes · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "Exendin-4 Fc fusion protein" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Type2 Diabetes Mellitus

  • AleniglipronPhase 36 trials

    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Obesity, Overweight, Chronic Weight Management

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.